Stock Exchange:
BRUSSELS
Sector:
Biotechnology
Sub-sector:
Development
Turnover last year:
1.268,6 M$ 2023
Profits last year:
-295,1 M$ 2023
Activity: Development of differentiated therapies for the treatment of serious autoimmune diseases.
https://www.argenx.com/